{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:58:55Z","timestamp":1790697535325,"version":"4.1.0"},"reference-count":21,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Underrepresentation of minority groups in clinical trials exacerbates health disparities and limits the generalizability of findings. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that disproportionately affects certain racial and ethnic groups, yet the extent to which trial enrollment reflects disease burden remains unclear. Misalignment between disease prevalence and trial representation may delay treatment development and increase the economic burden associated with late diagnosis and suboptimal management. To evaluate racial and ethnic representation in completed U.S.-based ATTR-CM clinical trials by comparing observed participant enrollment with expected enrollment based on disease prevalence, and to assess whether demographic reporting and representation improved following the 2017 Food and Drug Administration (FDA) Final Rule. Methods: This systematic review assessed US-based ATTR clinical trials registered on ClinicalTrials.gov through 2025 (search date: February 12, 2025). Only completed trials with publicly available results were included. Demographic data were extracted at the trial level. For each group, an enrollment fraction (EF) was calculated as observed enrollment \u00f7 expected enrollment, based on the Cardiac Amyloidosis Registry Study (CARS) prevalence; adequacy was defined as EF \u22650.75. Results: Of the 264 clinical trials on ATTR identified, 16 met the inclusion criteria. African American individuals\/individuals of African descent had EFs below the adequacy threshold of 0.75 across all reviewed trial phases compared with their Asian or White counterparts. Following implementation of the FDA Final Rule in 2017, reporting of demographic data increased in the overall study population (from 60% to 83.3%). Although the racial distribution remained significantly different from the expected population distribution in both periods, the enrollment fraction for Black participants declined from 0.291 before 2017 to 0.125 after 2017, with similar decreases observed among other minority groups. Conclusions: Black individuals remain substantially underrepresented in US-based ATTR-CM clinical trials despite improved demographic reporting after the 2017 FDA Final Rule. Actionable strategies, including community engagement, diversification of trial sites, enrollment targets, and sponsor accountability, are urgently needed to improve representativeness and expand access.<\/jats:p>","DOI":"10.31083\/rcm53698","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:11Z","timestamp":1790693831000},"source":"Crossref","is-referenced-by-count":0,"title":["Demographic Representation in Clinical Trials for Transthyretin-Associated Cardiac Amyloidosis: A Systematic Review"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2210-0875","authenticated-orcid":true,"given":"Dimitri","family":"Ford","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chima","family":"Amadi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Chandora","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Gold","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Emory School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanelle","family":"Brodeur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan","family":"Azees","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bakinde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anekwe E.","family":"Onwuanyi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshaleen Henriques","family":"King","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Critical Care, Department of Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021; 42: 1554\u20131568.","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circulation. Heart Failure. 2019; 12: e005407.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal. 2015; 36: 2585\u20132594.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2023; 81: 1076\u20131126.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Carry BJ, Young K, Fielden S, Kelly MA, Sturm AC, Avila JD, et al. Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records. JACC. CardioOncology. 2021; 3: 550\u2013561.","DOI":"10.1016\/j.jaccao.2021.07.002"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Nouvini R, Parker PA, Malling CD, Godwin K, Costas-Mu\u00f1iz R. Interventions to increase racial and ethnic minority accrual into cancer clinical trials: A systematic review. Cancer. 2022; 128: 3860\u20133869.","DOI":"10.1002\/cncr.34454"},{"key":"ref8","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health. Policy and Regulation on ClinicalTrials.gov Registration and Reporting. Available at: https:\/\/grants.nih.gov\/policy-and-compliance\/policy-topics\/clinical-trials\/reporting\/understanding (Accessed: 28 August 2025)."},{"key":"ref9","unstructured":"National Institutes of Health, Department of Health and Human Services. Clinical Trials Registration and Results Information Submission. Final rule. Federal register. 2016; 81: 64981\u201365157."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720\u20132726.","DOI":"10.1001\/jama.291.22.2720"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Stern LK, Grodin JL, Maurer MS, Ruberg FL, Patel AR, Khouri MG, et al. The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology. Journal of Cardiac Failure. 2024; 30: 669\u2013678.","DOI":"10.1016\/j.cardfail.2023.09.016"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Hantel A, Luskin MR, Garcia JS, Stock W, DeAngelo DJ, Abel GA. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Advances. 2021; 5: 4352\u20134360.","DOI":"10.1182\/bloodadvances.2021005148"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2024; 390: 132\u2013142.","DOI":"10.1056\/NEJMoa2305434"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Judge DP, Alexander KM, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs SDJ, et al. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology. 2025; 85: 1003\u20131014.","DOI":"10.1016\/j.jacc.2024.11.042"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic\/Latino Ancestry. JAMA. 2019; 322: 2191\u20132202.","DOI":"10.1001\/jama.2019.17935"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Khedraki R, Saef J, Martens P, Martyn T, Sul L, Hachamovitch R, et al. Race, Genotype, and Prognosis in Black Patients With Transthyretin Cardiac Amyloidosis. The American Journal of Cardiology. 2024; 216: 66\u201376.","DOI":"10.1016\/j.amjcard.2024.01.009"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Shankar B, Yanek L, Jefferson A, Jani V, Brown E, Tsottles D, et al. Race and Socioeconomic Status Impact Diagnosis and Clinical Outcomes in Transthyretin Cardiac Amyloidosis. JACC. CardioOncology. 2024; 6: 454\u2013463.","DOI":"10.1016\/j.jaccao.2024.05.001"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020; 142: e7\u2013e22.","DOI":"10.1161\/CIR.0000000000000792"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020; 141: 1214\u20131224.","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Flores LE, Frontera WR, Andrasik MP, Del Rio C, Mondr\u00edguez-Gonz\u00e1lez A, Price SA, et al. Assessment of the Inclusion of Racial\/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials. JAMA Network Open. 2021; 4: e2037640.","DOI":"10.1001\/jamanetworkopen.2020.37640"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Thakur N, Lovinsky-Desir S, Appell D, Bime C, Castro L, Celed\u00f3n JC, et al. Enhancing Recruitment and Retention of Minority Populations for Clinical Research in Pulmonary, Critical Care, and Sleep Medicine: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine. 2021; 204: e26\u2013e50.","DOI":"10.1164\/rccm.202105-1210ST"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM53698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:58:26Z","timestamp":1790693906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM53698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03880-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm53698","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"53698"}}